GLP1R and chronic kidney disease: The seemingly discrepant findings between our results and those of the CVD‐REAL Nordic study could be attributable to chance and/or the presence of different baseline characteristics including ethnicity, the prevalence of underlying chronic kidney disease or AF (9% patients already have AF at baseline in the CVD‐REAL Nordic study), and a different drug prescription including the use of insulin, glitazone, and glucagon-like peptide-1 receptor agonist.